Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 4/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | KCNA5 | P22460 | 5/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.43 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.40 |
| ▸ | SCN1A | P35498 | 2/20 | 0.40 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.40 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.38 |
| ▸ | DRD1 | P21728 | 2/20 | 0.38 |
| ▸ | HRH1 | P35367 | 2/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL9522591 | 0.98 | SLC6A2 (0.45) | SLC6A2SLC6A4SLC6A3TSHRKCNA5 | |
| SCHEMBL29157757 | 0.83 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3TSHRKCNA5 | |
| SCHEMBL177936 | 0.81 | SLC6A2 (0.45) | SLC6A2SLC6A4SLC6A3TSHRKCNA5 | |
| SCHEMBL506747 | 0.81 | KCNA5 (0.50) | SLC6A2SLC6A4SLC6A3TSHRKCNA5 | |
| SCHEMBL6551622 | 0.78 | KCNA5 (0.51) | SLC6A2SLC6A4SLC6A3TSHRKCNA5 | |
| SCHEMBL28438631 | 0.77 | SLC6A2 (0.45) | SLC6A2SLC6A4SLC6A3TSHRKCNA5 | |
| SCHEMBL6357883 | 0.77 | SLC6A2 (0.45) | SLC6A2SLC6A4SLC6A3TSHRKCNA5 | |
| SCHEMBL28858566 | 0.77 | SLC6A2 (0.45) | SLC6A2SLC6A4SLC6A3TSHRKCNA5 | |
| SCHEMBL3049830 | 0.77 | SLC6A2 (0.54) | SLC6A2SLC6A4SLC6A3TSHRKCNA5 | |
| SCHEMBL29914092 | 0.77 | SLC6A2 (0.54) | SLC6A2SLC6A4SLC6A3TSHRKCNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8993773-B2 | Process to prepare pioglitazone via several novel intermediates | CADILA HEALTHCARE LIMITED (IN) | 2015-03-31 | — | — | US | disclosed |
| US-20140088127-A1 | NOVEL PROCESS TO PREPARE PIOGLITAZONE VIA SEVERAL NOVEL INTERMEDIATES | CADILA HEALTHCARE LIMITED (IN) | 2014-03-27 | — | — | US | disclosed |
| US-8445685-B2 | Process to prepare pioglitazone via several novel intermediates | CADILA HEALTHCARE LIMITED (IN) | 2013-05-21 | — | — | US | disclosed |
| US-8173816-B2 | Process to prepare pioglitazone via several novel intermediates | CADILA HEALTHCARE LIMITED (IN) | 2012-05-08 | — | — | US | disclosed |
| US-20120077848-A1 | NOVEL PROCESS TO PREPARE PIOGLITAZONE VIA SEVERAL NOVEL INTERMEDIATES | CADILA HEALTHCARE LIMITED (IN) | 2012-03-29 | — | — | US | disclosed |
| US-20110021576-A1 | NOVEL PROCESS TO PREPARE PIOGLITAZONE VIA SEVERAL NOVEL INTERMEDIATES | CADILA HEALTHCARE LIMITED (IN) | 2011-01-27 | — | — | US | disclosed |
| US-7863300-B2 | Process to prepare pioglitazone via several novel intermediates | CADILA HEALTHCARE LIMITED (IN) | 2011-01-04 | — | — | US | disclosed |
| US-7671207-B2 | Process to prepare pioglitazone via several novel intermediates | CADILA HEALTHCARE LIMITED (IN) | 2010-03-02 | — | — | US | disclosed |
| US-7465801-B2 | Process to prepare pioglitazone via several novel intermediates | CADILA HEALTHCARE LIMITED (IN) | 2008-12-16 | — | — | US | disclosed |
| US-20080300282-A1 | Novel process to prepare pioglitazone via several novel intermediates | CADILA HEALTHCARE LIMITED (IN) | 2008-12-04 | — | — | US | disclosed |
| US-20080004446-A1 | Novel process to prepare pioglitazone via several novel intermediates | CADILA HEALTHCARE LIMITED (IN) | 2008-01-03 | — | — | US | disclosed |
| EP-0586556-B1 | SUBSTITUTED 2,6-SUBSTITUTED PYRIDINE HERBICIDES | ROHM & HAAS (US) | 1997-04-16 | — | — | EP | disclosed |
| EP-0586556-A1 | SUBSTITUTED 2,6-SUBSTITUTED PYRIDINE HERBICIDES. | MONSANTO CO (US) | 1994-03-16 | — | — | EP | disclosed |
| US-5169432-A | 2-and/or 6-fluoroalkyl substituted and a carbonyl oxy(thio) ester or a heterocyclo-carbonyl at the 3 or 5 position | MONSANTO COMPANY (US) | 1992-12-08 | — | — | US | disclosed |
| WO-1992020659-A1 | SUBSTITUTED 2,6-SUBSTITUTED PYRIDINE HERBICIDES | MONSANTO COMPANY (US) | 1992-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004446-A1 | Novel process to prepare pioglitazone via several novel intermediates | PPARD, PPARG, PPARA | SLC6A2 3596/4885SLC6A4 1946/4885SLC6A3 2240/4885 |
| US-20140088127-A1 | NOVEL PROCESS TO PREPARE PIOGLITAZONE VIA SEVERAL NOVEL INTERMEDIATES | PPARD, PPARG, PPARA | SLC6A2 3856/4885SLC6A4 2260/4885SLC6A3 2730/4885 |
| US-20080300282-A1 | Novel process to prepare pioglitazone via several novel intermediates | PPARD, PPARG, PPARA | SLC6A2 3856/4885SLC6A4 2260/4885SLC6A3 2730/4885 |
| US-20120077848-A1 | NOVEL PROCESS TO PREPARE PIOGLITAZONE VIA SEVERAL NOVEL INTERMEDIATES | PPARD, PPARG, PPARA | SLC6A2 3856/4885SLC6A4 2260/4885SLC6A3 2730/4885 |
| US-20110021576-A1 | NOVEL PROCESS TO PREPARE PIOGLITAZONE VIA SEVERAL NOVEL INTERMEDIATES | PPARD, PPARG, PPARA | SLC6A2 3856/4885SLC6A4 2260/4885SLC6A3 2730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.